Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Rang în acțiuni #3071
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Preț acțiune
$95.08
Capitalizare de piață
$5.98B
Schimbare (1 zi)
4.09%
Schimbare (1 an)
437.19%
Țară
US
Tranzacționează Kodiak Sciences Inc. (KOD)

Categorie

Healthcare
Istoricul spliturilor pentru Kodiak Sciences Inc. (KOD)
Acțiunea Kodiak Sciences Inc. (simbol: KOD) a trecut printr-un total de 1 splituri.
Cel mai recent split a avut loc pe Feb 23, 2022.
O acțiune KOD cumpărată înainte de Feb 23, 2022 este echivalentă astăzi cu 5 acțiuni KOD.
Listă splituri acțiuni
An Split Multiplu Multiplu cumulativ
2022-02-23 5:1 x5 x5
Splituri pentru companii similare sau competitori
Companie Număr total de splituri Multiplu cumulativ Țara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL